Home Biosimilar Antibodies Protein Tyrosine Kinase ALK Ascrinvacumab (Anti-ACVRL1 / ALK-1)
For research use only. Not for use in humans.

Ascrinvacumab (Anti-ACVRL1 / ALK-1)

Synonyms: ACVRL1,ALK1

Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD.

Ascrinvacumab (Anti-ACVRL1 / ALK-1)

Quality Control

Batch: Purity: 99% Protein concentration: 9.323mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation ALK Others
TAE684 (NVP-TAE684) 85
AP26113-analog (ALK-IN-1) 5 EGFR(C797S/del19),IGF1R,EGFR(del19)
GSK1838705A 18 Insulin Receptor,IGF-1R
AZD3463 8 IGF-1R
ASP3026 4
NVL-655 (Neladalkib) 1 ROS1,TrkB,FAK
Envonalkib 0
TL13-112 0
ZX-29 0
MS4078 0
Ensartinib dihydrochloride 8 TPM3-TRKA,GOPC-ROS1,TRKC
Belizatinib (TSR-011) 0 TrkC,TrkB,TrkA
Repotrectinib (TPX-0005) 15 Trk receptor,ROS1,Src
APG-2449 0
Iruplinalkib 0 ROS1
Conteltinib(CT-707) 0 Pyk2,FAK
Itacnosertib (TP-0184) 0
Zilurgisertib fumarate 0
ALK inhibitor 1 0 FAK,TSSK2
X-376 0
HG-14-10-04 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD.

Product Details

CAS No. 1463459-96-2
Molecular Weight 150 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07623525 RECRUITING Hereditary Hemorrhagic Telangiectasia; Pulmonary Arterial Hypertension Diagonal Therapeutics, Inc. 2026-06-04 PHASE1; PHASE2
NCT01642082 COMPLETED Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Transitional Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma Gynecologic Oncology Group 2012-09 PHASE2
NCT01720173 COMPLETED Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma Gynecologic Oncology Group 2012-11-05 PHASE2
NCT01911273 TERMINATED Drug: PF-03446962 Carcinoma, Hepatocellular Pfizer 2013-10 PHASE2
NCT01620970 COMPLETED Drug: PF03446962 Transitional Cell Carcinoma of Bladder Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2012-03-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.